Amprologix (@amprologix.bsky.social)

Epidermicin NI01, has been featured in EMJ Reviews following a presentation by CSO @matupton.bsky.social at @escmid.bsky.social Global 2025. The data highlights efficacy in MRSA wound infections, and low risk of triggering allergic reactions - a promising step forward in the fight against AMR.

loading . . .

Epidermicin NI01, a First-in-Class Peptide Antibiotic Candidate, Has Potent Efficacy in a Robust MRSA Wound Infection Model and Low Allergic Reaction Liabilities Over 10% of antibiotic prescriptions are for skin infections.1,2 New therapeutic approaches are required, and new modalities may be... https://www.emjreviews.com/microbiology-infectious-diseases/abstract/epidermicin-ni01-a-first-in-class-peptide-antibiotic-candidate-has-potent-efficacy-in-a-robust-mrsa-wound-infection-model-and-low-allergic-reaction-liabilities-j100125/